Methods of producing antibodies to neonatal Fc receptor (FcRn)

Patent metadata

Field	Value
Publication number	US-9862768-B2
Application number	US-201615139784-A
Country	US
Kind code	B2
Filing date	Apr 27, 2016
Priority date	Jun 2, 2011
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

First claim

What is claimed is:

1. A method of producing an antibody specific to a neonatal Fc receptor (FcRn), the method comprising:
(i) culturing, under conditions suitable for expression of the antibody, a host cell comprising a first nucleic acid encoding a light chain variable region (V L ) of the antibody specific to the FcRn, and a second nucleic acid encoding a heavy chain variable region (V H ) of the antibody specific to the FcRn, wherein each of the first nucleic acid and the second nucleic acid is in operable linkage to a promoter; and
(ii) collecting the antibody specific to the FcRn produced in (i);

wherein:
the V L comprises a V L CDR1 that comprises the amino acid sequence of TGTGSDVGSYNLVS (SEQ ID NO:14); a V L CDR2 that comprises the amino acid sequence of GDSQRPS (SEQ ID NO:15); and a V L CDR3 that comprises the amino acid sequence of SSYAGSGIYV (SEQ ID NO:12) or ASYAGSGIYV (SEQ ID NO:13); and
the V H comprises a V H CDR1 that comprises the amino acid sequence of EYAMG (SEQ ID NO:22); a V H CDR2 that comprises the amino acid sequence of SIGSSGGQTKYADSVKG (SEQ ID NO:23); and a V H CDR3 that comprises the amino acid sequence of LAIGDSY (SEQ ID NO:24).

2. The method of claim 1 , wherein the V L comprises the amino acid sequence of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:11.

3. The method of claim 1 , wherein the V H comprises the amino acid sequence of SEQ ID NO:9.

4. The method of claim 2 , wherein the V H comprises the amino acid sequence of SEQ ID NO:9.

5. The method of claim 1 , wherein the second nucleic acid further encodes a heavy chain constant region (C H ), which has a deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID NO:17.

6. The method of claim 1 , wherein the first nucleic acid and the second nucleic are on the same expression vector.

7. The method of claim 1 , wherein the first nucleic acid and the second nucleic are on two different expression vectors.

8. The method of claim 1 , wherein the host cell is a bacterial cell, a yeast cell, an insect cell, a plant cell, or a mammalian cell.

9. The method of claim 8 , wherein the host cell is a mammalian cell.

10. The method of claim 9 , wherein the mammalian cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, a NS0 myeloma cell, a SP2 cell, a COS cell, and a mammary epithelial cell.

11. The method of claim 9 , wherein the host cell lacks an endogenous dihydrofolate reductase (dhfr − ).

12. The method of claim 11 , wherein the first nucleic acid or second nucleic acid further encodes a DHFR protein.

Assignees

• Dyax Corp

Inventors

• Sexton Daniel J
• Tenhoor Christopher
• Viswanathan Malini

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title